Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2008 |
| Contact: | Timothy Kuzel, MD |
| Phone: | 312-695-1301 |
Dose-escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 Topically Administered to Patients With Cutaneous Metastatic Melanoma
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for
four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic
melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on
histological remission of cutaneous metastatic melanoma and induction of apoptotic
biomarkers.
four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic
melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on
histological remission of cutaneous metastatic melanoma and induction of apoptotic
biomarkers.
Inclusion Criteria:
- Study Participants must be 18 years or older.
- Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be
removed with surgery.
- Study Participants may have been previously treated with chemotherapy or
immunotherapy but not with in 4 weeks of first dose of study treatment.
We found this trial at
1
site
675 N Saint Clair St # 21-100
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 695-1156
Robert H. Lurie Comprehensive Cancer Center at Northwestern University The cancer center was first established...
Click here to add this to my saved trials
